Potential Celiac Patients: A Model of Celiac Disease Pathogenesis by Sperandeo, Maria Pia et al.
Potential Celiac Patients: A Model of Celiac Disease
Pathogenesis
Maria Pia Sperandeo
1, Antonella Tosco
1, Valentina Izzo
1, Francesca Tucci
1, Riccardo Troncone
1, Renata
Auricchio
1, Jihane Romanos
2, Gosia Trynka
2, Salvatore Auricchio
1, Bana Jabri
3, Luigi Greco
4*
1European Laboratory for Food Induced Disease, University of Naples Federico II, Naples, Italy, 2Department of Genetics, University Medical Centre of Groningen,
University of Groningen, Groningen, The Netherlands, 3Department of Medicine, Department of Pathology and Department of Paediatrics, University of Chicago, Chicago,
Illinois, United States of America, 4Department of Pediatrics, University of Naples Federico II, Naples, Italy
Abstract
Background and Aim: Potential celiacs have the ‘celiac type’ HLA, positive anti-transglutaminase antibodies but no damage
at small intestinal mucosa. Only a minority of them develops mucosal lesion. More than 40 genes were associated to Celiac
Disease (CD) but we still do not know how those pathways transform a genetically predisposed individual into an affected
person. The aim of the study is to explore the genetic features of Potential CD individuals.
Methods: 127 ‘potential’ CD patients entered the study because of positive anti-tissue transglutaminase and no mucosal
lesions; about 30% of those followed for four years become frankly celiac. They were genotyped for 13 polymorphisms of
‘candidate genes’ and compared to controls and celiacs. Moreover, 60 biopsy specimens were used for expression studies.
Results: Potential CD bear a lighter HLA-related risk, compared to celiac (x
2=48.42; p value=1 610
28). They share most of
the polymorphisms of the celiacs, but the frequency of c-REL* G allele was suggestive for a difference compared to celiac
(x
2=5.42; p value=0.02). One marker of the KIAA1109/IL-2/IL-21 candidate region differentiated potentials from celiac
(rs4374642: x2=7.17, p value=0.01). The expression of IL-21 was completely suppressed in potentials compared to celiacs
(p value=0.02) and to controls (p value=0.02), in contrast IL-2, KIAA1109 and c-REL expression were over-expressed.
Conclusions: Potential CD show genetic features slightly different from celiacs. Genetic and expression markers help to
differentiate this condition. Potential CD is a precious biological model of the pathways leading to the small intestinal
mucosal damage in genetically predisposed individuals.
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Introduction
The pathway of gluten-induced immunoresponse in Celiac
Disease (CD) is not yet completely clarified to date, but a
tremendous progress was gained recently [1,2] by the discovery of
candidate genes identified by genome wide association studies
(GWAS) [3–5]. More than 40 candidate genes were discovered,
each of them giving a minute contribution to the genomic variance
in CD [6]. Only a functional profile of the gluten induced
immunoresponse will shed light into the complex interaction of
these molecules. The way to progress is to draw reliable pieces of
functional pathways that may build up the puzzle of the gluten-
induced immunoresponse. New genes, added to HLA, account for
around 50% of the genetic risk. Even though relatively
homogeneous, CD is probably not one disease, and different
pathways and risk factors can be probably distinguished. The
progressive stages of the disease are a resource to better
understand the role of the genes identified up to date.
Alongside theHLA, a robustassociation was identified byGWAS
on chromosome 4q27, containing the IL-2, IL-21 and KIAA1109
gene cluster [3]. We did confirm this strong association in our CD
patients and controls, originated from the same region of Southern
Italy (unpublished data). The discovery of a heritable variation in
this gene cluster points to a direct involvement of these cytokines. In
active CD there is an enhanced production of IL-21 [1]. The
quiescence of the active phase of CD, obtained by a gluten free diet
(GFD), reverts the IL-21 activity to normal values. When mucosal
biopsies from treated CD patients are challenged with gluten
peptides, IL-21 is again over expressed [1]. IL-21 induces, in active
CD, T-bet expression [7]. The over expression of IL-21 is likely to
play a crucial role in the activation of cytotoxic T-cell leading to
epithelial cell death and mucosal destruction of active CD [8].
c-REL and TNFAIP3 are key mediators in the nuclear factor
kappa B (NF-kB) inflammatory signalling pathway [5]. We
suggested previously an early involvement of the NF-kB pathway
in the gluten-induced inflammation either in acute CD as well as
in gliadin exposed small intestinal mucosa tissue culture [9]. We
proposed that, through the NF-kB pathway, gliadin peptides could
stimulate iNOS expression in IFN-c treated macrophages from
non-celiac patients [10].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21281So far, genetic studies gave a solid base to explore biological
models of gluten-induced immune response, but, no genotype-
phenotype association could be found for any of the above listed
candidate genes [11].
Recently the clinical presentation of CD underwent substantial
changes: from classical malabsorption driven picture to light or
absent symptoms associated to moderate damage of intestinal
mucosa. The term ‘potential CD’ was assigned to individuals with
proper DQ2 or DQ8, production of anti Transglutaminase (anti
TTG) antibodies and normal small intestinal mucosa, classified as
Marsh 0 (no damage) or Marsh 1 stage (unspecific intra epithelial
infiltration only). These are also defined ‘‘serological positive
cases’’ [12–14]. Potential patients suggest that the development of
adaptive anti-gluten immunity is not sufficient to develop villous
atrophy. This is supported by animal models showing that
inflammatory anti-gluten responses are not sufficient to develop
mucosal lesions [2]. Thus, we can subgroup individuals into three
groups: controls, patients who developed antibodies but no
intestinal lesions (M0 and M1 potentials) and patients with
antibodies and villous atrophy (overt CD). Analyzing differences
among these subgroups may shed light into the genes differentially
involved in development of adaptive anti-gluten immunity
(different between control and potential) and tissue lesions
(different between potential and CD), as well as genes involved
in all steps of CD pathogenesis (different between control and
potential, and potential and CD).
We have a sizeable cohort of a living experimental model of CD:
intestinal production of anti TTG antibodies but no specific
mucosal damage. The vast majority of these individuals have no
symptoms and may be grouped into low-medium-high anti-TTG
producers, but all have a small intestinal mucosa with normal villi/
crypt ratio, none or moderate IEL infiltration and normal epithelial
layer. Over a prolonged follow up on gluten containing diet only
about 1/3
rd develop mucosal damage, most frequently not
associated to symptoms [14]. The reasons why potential CD do
not show any degree of substantial mucosal damage, albeit the
presence of all the features of CD, is the question, whose answer can
contribute to the understanding of the pathogenesis of CD.
Our aim is to explore the presence of genetic and expression factors
that may differentiate potential patients from overt CD patients.
Results
HLA typing
The HLA genotype of 127 potential CD cases was compared to
that of 311 Celiacs previously reported by us [15]. Potential CD
less frequently belong to high risk classes (double DQ2 or DQ2 in
trans), while they show more frequently very low or moderate
HLA-related risk (Table 1). We observed more cases in the HLA
class at lower risk among potentials as compared to full celiacs:
these cases bear half of the DQ2 heterodimer, either DQB1*02 or
DQA1*05 only. To avoid a selection bias we did not excluded
these potential cases, who produced anti TGASE and were anti
Endomysium positive.
When we compared the HLA risk between M0 and M1 potential
cases we didnot observe anydifference(x
2=1.92;p=0.75,datanot
shown). Cases who developed small intestinal atrophy during follow
up did not show an HLA distribution different from those who
remained potential (x
2=5.17; p=0.27, data not shown).
Eight Candidate Genes SNPs genotype and allele
distribution
Hunt et al. [4] reported 8 new CD risk loci, located in different
chromosomes. The size of the sample of the potential CD has no
sufficient power to differentiate the polymorphisms distribution
between potential CD and controls: nevertheless we found that
three SNPs in LPP, c-REL and CCR regions respectively showed
significant differences between controls and potential CD in their
genotype distribution (Table 2). Seven out of 8 SNPs analyzed
showed no significant differences between potential and CD cases
in their genotype distribution. The SNP marking the c-REL gene
showed the GG genotype 2.5 times more often in potentials versus
‘full’ CD and versus Controls (Table 2).
By analysis of allele distribution, we found that both LPP*A, c-
REL*G, and CCR*A alleles were significantly associated to
potential cases compared to controls (Table 3). Only c-REL*G
allele was significantly associated with potential cases when
compared to CD cases (Table 3).
None of the candidate genes distinguished between M0 and M1
potential cases (data not shown). M0 patients were not different
from controls, except for CCR gene. M1 patients reinforced the
significant differential distribution of the c-REL genotype when
compared to CD: again the GG genotype was about three times
more frequent in M1 patients compared to CD patients. The same
trend, with good statistical significance, is observed between M1
potential and controls not only for c-REL but also for LPP gene
(Table S1).
The eleven cases who developed small intestinal atrophy during
follow up did not show an allelic and genotypic distribution
different from those who remained potential, maybe because of
the sample size that was too small to evaluate differences (Table S2
and S3).
Five Candidate SNPs on the 4q genomic region
Despite the limited sample size we found that three SNPs in the
4q genomic region showed significant differences between controls
and potential CD patients (rs4374642, rs13119723 and rs6840978)
in their genotype distribution. In addition, we found also significant
differences between potential CD and CD patients for three SNPs
(rs4374642, rs13119723 and rs6822844) (Table 4).
The rs4374642, rs13119723 and rs6840978 SNPs, respectively,
were significantlyassociated when Potential CD cases were compared
to Controls (Table 5). In contrast, only the rs4374642*T was the risk
allele associated with potential cases when compared to CD cases
(Table 5).
Cases who developed small intestinal atrophy during follow up
did not show an allelic and genotypic distribution different from
those who remained potential (Table S2 and S3).
Expression Studies
The expression of the IL-21 gene was completely suppressed in
potential CD, as compared to CD (Mann-Whitney test; Rank test,
Table 1. HLA risk classes distribution.
HLA Haplotype
Risk Class
311 CD
cases
127 Potential
CD cases
Double DQ2 74 (24%) 12 (9.4%)
DQ2 in trans 117 (38%) 23 (18.1%)
DQ2 single 79 (25%) 48 (37.8%)
DQ8 or DQB1*02 (DQA1*05 negative) 13 (4%) 21 (16.5%)
NoDQ2/NoDQ8 28 (9%) 23 (18.0%)
x
2=48.42 p=1610
8
doi:10.1371/journal.pone.0021281.t001
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expression in potential CD either completely normal as well as
infiltrated were consistently lower that the controls(p=0.02 forboth
stages).SoIL-21expressionismarkedlysuppressedinthesepatients.
Celiac patients revert completely IL-21 at the levels of controls after
at least one year of GFD. But IL-21 expression in celiacs after GFD
is still higher than that of the potential CD (p=0.01).
IL-2 is over-expressed in M0 potential CD as compared to
controls (p=0.03) and to celiacs on GFD (p=0.01) (Fig. 1B).
Fig. 1C shows the expression of the KIAA1109 gene: its pattern is
very similar to that of IL-2. It may be noted that M1 cases have an
expression 4 times lower than M0 potentials (p=0.04) but a
marked increase over the controls (p,0.01) and of about 4 folds
over the celiacs (p=0.01). Celiacs on GFD show higher values
than acute phase celiacs (p=0.03) and controls (p=0.02).
The expression of the c-REL gene was higher in M0 potentials,
compared to CD cases (p=0.04) and to controls (p=0.03) (Fig. 1D).
We explored the relationship between the expression data with
the genotype of the same patients for the same gene. We could not
recover all DNA samples from the patients, whose RNA was used
for expression experiments. Nevertheless we could not found a
specific genotype related to the expression value for the same gene,
as reported previously [5].
Discussion
This work attempts to explore the genetic and expression
profiles of a special set of individuals in the CD domain. Potential
Celiac patients, with positive serology and undamaged small
intestinal mucosa appear to be differently associated with some
genetic risk factors compared to full blown CD patients.
Potential CD bears a load of HLA-related CD risk significantly
lighter than that of CD cases, with a mix of high-intermediate-low
risk different from that observed in CD cases. No difference in
HLA profile was observed between M0 and M1 potential patients,
neither between the cases who developed full blow disease and
those who remained potential at follow up. Subjects without the
classical DQ2 or DQ8 heterodimers were double in potential (23,
18.0%) than in classical celiacs (28, 9.0%), but they produced
antibodies against Human Tissue Tranglutaminase, with positive
Endomysial antibodies, just as much as the DQ2 positive cases. In
addition we could find no discrimination on the outcome between
the DQ2/DQ8 carriers and those who carried only half of the
heterodimers. This is one of the results of this work and should not
produce a selection bias. Three cases were questionable on the
basis of having only DQA1*01 /DQB1*0501: but this haplotype
was previously described in celiac disease [16]. Although they may
not represent the typical potential celiac, we did not exclude them,
to avoid selection bias. We better accept that only 3/127 cases
may not show the full pattern of the majority of the cohort.
We identified six polymorphisms suggestive to be differently
distributed between controls and potential CD: KIAA1109, IL-21,
LPP, c-REL and CCR. We suppose that these factors are
implicated at some stages of CD pathogenesis, and that, as for
HLA, there may be a ‘‘gene-dosage effect’’. Furthermore, c-REL
and KIAA1109 are more expressed in M0 potential patients
Table 2. Association results for 8 celiac non-HLA risk variants.
Controls Potential CD x
2 p value CD cases Potential CD x
2 p value
RGS1 (rs2816316) AA 488 (68,6%) 88 (69.3%) 0.32 0.85 463 (72,7%) 88 (69.3%) 2.67 0.26
AC 193 (27.1%) 35 (27.6%) 166 (26.1%) 35 (27.6%)
CC 30 (4.2%) 4 (3.1%) 8 (1.3%) 4 (3.1%)
IL18RAP (rs917997) AA 42 (5.9%) 7 (5.5%) 1.07 0.58 41 (6.4%) 7 (5.5%) 0.69 0.71
AG 246 (34.6%) 50 (39.4%) 227 (35.6%) 50 (39.4%)
GG 423 (59.5%) 70 (55.1%) 369 (57.9%) 70 (55.1%)
LPP (rs1464510) AA 108 (15.2%) 28 (22.0%) 7.58 0.02 152 (23.9%) 28 (22.0%) 0.77 0.68
AC 362 (50.9%) 70 (55.1%) 324 (50.9%) 70 (55.1%)
CC 241 (33.9%) 29 (22.8%) 161 (25.3%) 29 (22.8%)
OLIG3 (rs2327832) AA 480 (67.7%) 84 (66.7%) 0.05 0.98 399 (63.6%) 84 (66.7%) 0.81 0.67
AG 202 (28.5%) 37 (29.4%) 208 (33.2%) 37 (29.4%)
GG 27 (3.8%) 5 (4.0%) 20 (3.2%) 5 (4.0%)
TAGAP (rs1738074) AA 125 (17.6%) 26 (20.5%) 0.6 0.74 144 (22.6%) 26 (20.5%) 0.36 0.84
AG 354 (49.9%) 61 (48.0%) 305 (47.9%) 61 (48.0%)
GG 231 (32.5%) 40 (31.5%) 188 (29.5%) 40 (31.5%)
c-REL (rs842647) AA 404 (56.8%) 62 (48.8%) 9.84 0.01 359 (56.4%) 62 (48.8%) 10.8 0.01
AG 272 (38.3%) 50 (39.4%) 249 (39.1%) 50 (39.4%)
GG 35 (4.9%) 15 (11.8%) 29 (4.6%) 15 (11.8%)
CCR (rs6441961) AA 99 (13.9%) 25 (19.7%) 8.28 ,0.01 120 (18.8%) 25 (19.7%) 2.29 0.32
AG 318 (44.7%) 66 (52.0%) 293 (46.0%) 66 (52.0%)
GG 294 (41.4%) 36 (28.3%) 224 (35.2%) 36 (28.3%)
SCHIP1 (rs17810546) AA 610 (85.8%) 102 (80.3%) 2.56 0.28 526 (82.6%) 102 (80.3%) 0.92 0.63
AG 92 (12.9%) 23 (18.1%) 106 (16.6%) 23 (18.1%)
GG 9 (1.3%) 2 (1.6%) 5 (0.8%) 2 (1.6%)
doi:10.1371/journal.pone.0021281.t002
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adaptive anti-gluten immunity.
The SNP at c-REL gene shows a different distribution of the G
allele, as well as of the corresponding genotype, in potential CD
versus celiacs and versus controls. Unfortunately we were unable
to correlate the G allele of the polymorphic marker of the gene
with RNA expression, but we will explore further in more cases.
c-REL gene has been recently associated to CD but no significant
effect of the rs842647 polymorphism on gene expression was
observed [5]. In small-intestine tissue from controls and from
treated and untreated celiac patients, c-REL gene did not show
significant differential expression among the three groups [5]. c-
REL, a subunit of the NF-kB complex, is crucial for the regulation
of this major nuclear factor for the innate and adaptive immunity
Table 4. Association results for 5 celiac non-HLA risk variants, located on 4q27 chromosome.
Controls Potential CD x
2 p value CD cases Potential CD x
2 p value
KIAA1109 (rs4374642) CC 4.52 0.03 4 (1.2%) 7.22 0.03
CT 63 (14.2%) 9 (7.1%) 53 (15.3%) 9 (7.1%)
TT 381 (85.8%) 118 (92.9%) 290 (83.6%) 118 (92.9%)
KIAA1109 (rs13119723) AA 397 (88.6%) 104 (81.3%) 5.99 0.05 290 (84.1%) 104 (81.3%) 8.16 0.02
AG 48 (10.7%) 21 (16.4%) 55 (15.9%) 21 (16.4%)
GG 3 (0.7%) 3 (2.3%) 3 (2.3%)
KIAA1109 (rs1127348) CC 16 (3.6%) 8 (6.3%) 2.05 0.36 9 (2.6%) 8 (6.3%) 3.51 0.17
CT 122 (27.5%) 37 (29.1%) 103 (30.3%) 37 (29.1%)
TT 205 (68.8%) 82 (64.6%) 228 (67.1%) 82 (64.6%)
IL2/IL21 (rs6822844) GG 358 (80.1%) 103(79.8%) 0.35 0.84 267 (81.9%) 103(79.8%) 7.61 0.02
GT 82 (18.3%) 23 (17.8%) 59 (18.1%) 23 (17.8%)
TT 7 (1.6%) 3 (2.3%) 3 (2.3%)
IL21 (rs6840978) CC 363 (81.6%) 85 (72.0%) 17.94 ,0.01 222 (76.8%) 85 (72.0%) 4.5 0.10
CT 82 (18.4%) 29 (24.6%) 65 (22.5%) 29 (24.6%)
TT 4 (3.4%) 2 (0.7%) 4 (3.4%)
doi:10.1371/journal.pone.0021281.t004
Table 3. Association results of non-HLA SNPs alleles.
Potential CD and controls
SNP Locus A1 A2
Pot CD Cases,
Controls Ratios
MAF Pot
CD cases
MAF
controls x
2 p value
Odds ratio (95%
confidence interval)
rs2816316 RGS1 A C 214:44, 1169:253 0.17 0.18 0.08 0.77 1.05 (0.74–1.50)
rs917997 IL18RAP G A 193:65, 1092:330 0.25 0.23 0.48 0.49 0.90 (0.66–1.22)
rs1464510 LPP C A 129:129, 844:578 0.50 0.41 7.84 0.01 0.68 (0.52–0.89)
rs2327832 OLIG3 A G 207:49, 1162:256 0.19 0.18 0.17 0.68 0.93 (0.66–1.31)
rs1738074 TAGAP G A 143:115, 816:604 0.44 0.42 0.37 0.54 0.92 (0.70–1.20)
rs842647 c-REL A G 178:80, 1080:342 0.31 0.24 5.62 0.02 0.70 (0.53–0.94)
rs6441961 CCR G A 139:119, 906:516 0.46 0.36 8.99 ,0.01 0.66 (0.51–0.87)
rs17810546 SCHIP1 A G 231:27, 1312:110 0.10 0.08 2.17 0.14 0.72 (0.46–1.12)
Potential CD and CD patients
SNP Locus A1 A2
Pot CD cases.
CD cases Ratios
MAF Pot
CD cases
MAF CD
cases x
2 p value
Odds ratio (95%
confidence interval)
rs2816316 RGS1 A C 214:44, 1092:182 0.17 0.14 1.31 0.25 0.81 (0.56–1.16)
rs917997 IL18RAP G A 193:65, 965:309 0.25 0.24 0.10 0.75 0.95 (0.70–1.29)
rs1464510 LPP C A 129:129, 646:628 0.50 0.49 0.04 0.83 0.97 (0.74–1.27)
rs2327832 OLIG3 A G 207:49, 1008:248 0.19 0.20 0.05 0.82 1.04 (0.74–1.46)
rs1738074 TAGAP G A 143:115, 681:593 0.44 0.46 0.34 0.56 1.08 (0.83–1.42)
rs842647 c-REL A G 178:80, 967:307 0.31 0.24 5.43 0.02 0.71 (0.53–0.95)
rs6441961 CCR G A 139:119, 741:533 0.46 0.42 1.61 0.20 0.84 (0.64–1.10)
rs17810546 SCHIP1 A G 231:27, 1158:116 0.10 0.09 0.47 0.49 0.84 (0.55–1.33)
doi:10.1371/journal.pone.0021281.t003
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immune stimuli. The integral structure of c-REL is crucial for the
activation as well as for the termination of NF-kB induced
immunoresponse [18].
In conclusion, the finding of the different allele and genotype
distribution of this gene in the potential CD model does point to
the crucial role of NF-kB in the pathogenesis of the innate as well
as induced immune response in CD. Sustained activation of NF-
kB in intestinal mucosa of CD patients leads to prolonged
induction of inflammatory genes expression and thereby perpet-
uates the chronic inflammatory process. Our group produced
consistent evidence of the very early involvement of NF-kB
mechanism in the gliadin-induced innate immune response in CD
[9]. NF-kB is constitutively active in intestinal mucosa of patients
with untreated CD and reverts to normal values when gluten is
removed from the diet.
The polymorphic markers of the 4q candidate region show
significant differences between potential CD and CD cases.
Potential CD show a marked suppression of IL-21, below the
level of CD cases, celiacs on GFD and even of normal controls. IL-
2 and KIAA1109, on the contrary were both over-expressed in
M0 potential CD compared to M1, to celiacs and to controls. M1
cases show an IL-2 and KIAA1109 expression very similar to that
of CD.
The finding that the IL-21 gene differentiates potential from
controls suggests that it may be implicated also in the adaptive
anti-gluten immune responses. This is compatible with findings
indicating that IL-21 is produced by follicular helper cells and
plays a critical role in B cell differentiation. However IL-21 is also
implicated in tissue damage because of its ability to promote NK
activity and block regulatory T cells.
In accordance with the role of IL-21 in tissue damage and its
down regulation in the mucosa of potential CD patients we found
that the IL-21/IL-2 candidate region differentiates potential from
CD patients. Conversely, IL-2, which was found to be a critical
growth factor for Foxp3+ regulatory T cells, is highly expressed at
the transcriptional level in potential CD mucosa. Because Foxp3
regulatory T cells play a critical role in blocking effectors T cell
functions, these finding suggests that the level of IL-2 may be a
critical factor in the development of tissue damage.
Potentialpatients have most of the features of CD patients:theyhave
similar genes. produce the same antibodies but they lack the final
destructive phase of the gluten induced immunoresponse, the cytotoxic
destruction of small intestinal mucosa. No clinical, serological or
histological features could distinguish M0 from M1 patients up to now
[14], for the first time we can speculate that potential CD are a mixture
of two populations, with different non-HLA genetics and significant
differential expression of some candidate genes.
Those potential cases who developed full blow mucosal damage
on follow up, did not show any of the time 0 serologic markers
worse than those who remained potential over a prolonged follow
up. Similarly no genetic polymorphism, including HLA, could
predict the outcome of these potential cases. We observed the
same distribution of the HLA as well as of the non-HLA genes in
the cases who eventually become full blown celiacs.
The limit of this study is the relatively short follow up time of
this peculiar cohort of Potential CD cases: up to now there has
been no possibility to identify any marker (clinical, environmental,
serological or genetic) that could help to predict the time of
conversion from predisposition to CD to full blown disease. In
conclusion we cannot state that the cohort of potential celiacs who
have again show an undamaged intestinal mucosa after 4 to 6
years of follow up, will not eventually develop it later in life. We
can only observe that this group did not developed the full blown
disease after 4–6 years. But the genetic and expression features
point to the existence of a peculiar molecular profile, that may
help to identify cases who do not have the complete molecular
repertoire to develop the disease.
They may indeed be considered a live biological model of CD
pathogenesis, where the process is, for some time or even forever,
interrupted just before the final destructive phase.
Materials and Methods
Ethics statement
TheStudyProtocolwasapprovedbytheEthicsCommitteeofthe
University of Naples Federico II. Biopsies were taken during routine
Table 5. Association results of non-HLA SNPs Alleles, located on chromosome 4q27.
Potential CD and Controls
SNP Locus A1 A2
Pot CD Cases,
Controls Ratios
MAF Pot
CD cases
MAF
Controls x
2
p
value
Odds ratio (95%
confidence interval)
rs4374642 KIAA1109 T C 249:9, 823:63 0.03 0.07 4.44 0.03 2.12 (1.04–4.32)
rs13119723 KIAA1109 A G 229:27, 832:54 0.10 0.06 5.97 0.01 0.55 (0.34–0.89)
rs1127348 KIAA1109 T C 201:53, 732:154 0.21 0.17 1.61 0.20 0.80 (0.56–1.13)
rs6822844 IL2/IL21 G T 228:28, 796:96 0.11 0.10 0.01 0.94 0.98 (0.63–1.53)
rs6840978 IL21 C T 199:37, 802:82 0.16 0.09 8.04 ,0.01 0.55 (0.36–0.83)
Potential CD and CD patients
SNP Locus A1 A2
Pot CD Cases,
CD cases Ratios
MAF Pot
CD cases
MAF CD
cases x
2
p
value
Odds ratio (95%
confidence interval)
rs4374642 KIAA1109 T C 249:9, 622:58 0.03 0.08 7.17 0.01 2.58 (1.26–5.29)
rs13119723 KIAA1109 A G 229:27, 604:54 0.10 0.08 1.25 0.26 0.76 (0.47–1.23)
rs1127348 KIAA1109 T C 201:53, 552:120 0.21 0.18 1.10 0.29 0.82 (0.58–1.18)
rs6822844 IL2/IL21 G T 228:28, 592:58 0.11 0.09 0.87 0.35 0.79 (0.49–1.28)
rs6840978 IL21 C T 199:37, 503:69 0.16 0.12 1.92 0.17 0.74 (0.48–1.14)
doi:10.1371/journal.pone.0021281.t005
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guardian gave their informed consent about the endoscopic
procedures and the biopsy. Patients did not underwent blood or
specimen sampling over and above those requested by the routine
diagnostic procedures according to the ESPGHAN guidelines [19].
Subjects
1. 127 children (76 females, median age 6 years and 6 months,
range 18 months–16 years) were classified as ‘potential CD’ on
the basis of:
– Increased levels of anti-TTG (IgA anti Human Tissues
Transglutaminase) and Anti-Endomisium positive. Serum
EMA and anti TTG IgA were detected by indirect
immunofluorescence and by enzyme-linked immunosorbent
assay (ELISA) technique using a kit based on human
recombinant antigen respectively (Eu-tTg IgA Kit, Euro-
spital, Trieste).
– Architecturally normal small intestinal mucosa (M0 and M1)
on at least four mucosa samples, to minimize the possible
bias due to patchy lesions. Definition of the stage of lesion
was obtained by Marsh stages modified by Oberhuber [14].
At the first biopsy, patients underwent clinical and laboratory
assessment (CD-related auto antibodies, thyroid auto antibodies,
nutritional parameters, bowel inflammatory indexes). 50/127
(39.4%) patients belong to at risk groups: 32 were first-degree
Figure 1. Expression studies of candidate genes on RNA extracted from small intestinal mucosal biopsies.
doi:10.1371/journal.pone.0021281.g001
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e21281relatives of celiac patients, 18 were affected by autoimmune
diseases (11 type 1 diabetes and 7 thyroiditis). 105/127 (82.7%)
were asymptomatic; 21/127 showed symptoms attributable to
CD, 17 gastrointestinal (abdominal pain, weight loss, diarrhoea,
failure to thrive) and 4 extra intestinal (2 short stature, one
dilatative cardiomyopathy, one refractory anaemia). 21 symp-
tomatic patients went on GFD, the others continued on a normal
diet with a 6 monthly follow-up schedule. After two years they
were re-biopsied. The second biopsy was anticipated if symptoms
ensued.
The 21 patients on a GFD became negative for CD-related auto
antibodies but 6 of them did not show any clinical response to
GFD. 105/127 patients continued a gluten containing diet.
During follow-up CD serology became negative in about 15%
and antibody fluctuation was observed in 42% with transient
negativity for anti-TTG values. Four patients developed autoim-
mune disorders (1 type 1 diabetes and 3 thyroiditis), 1 patient
developed a vitamin K deficiency and began a GFD. 44/105
patients repeated a biopsy after 2 years of follow-up.13/44 (29.5%)
developed mucosa damage, all the others were invariant at the
control biopsy [14]. In conclusion, 35 children were considered
celiac patients: 23 patients were put on a GFD at the beginning of
the study because of symptoms, 1 patient was put on a GFD due to
appearance of symptoms during the follow-up and 11 patients
developed atrophy.
2. To evaluate genetic risk allele a cohort of 643 overt CD cases,
and 711 healthy controls were compared to the 127 potential
CD patients. Controls were randomly selected from a DNA
bank representing the healthy population of the region,
stratified for province. All originated from the same centre
and the same geographical area. Genotyping of the 4q
candidate gene was performed on a set of about 350 cases
and about 450 controls from the above sample.
3. To evaluate the HLA-related risk the 127 potential cases were
compared to a set of 311 overt cases from the same sample
described above and reported in Bourgey et al. [15].
Genotyping
HLA typing was performed using Eu-Gene Risk kit (EURO-
SPITAL). Cases were grouped into 5 HLA, as reported previously
[15]. Thirteen SNPs were genotyped using TaqMan technology
(Applied Biosystems) as described elsewhere [3,20]. Reactions
were performed on 7900HT Fast Real-Time PCR System
(Applied Biosystems).
Expression Studies
The expression of KIAA1109, IL-2 and IL-21 was analyzed in
mucosal biopsy samples from 17 CD cases, 21 potential CD
patients (7 M0 and 14 M1), 8 CD patients on GFD, and 14
controls using Real Time PCR by ‘Assays-On-Demand’ (Applied
Biosystems). Controls underwent endoscopy for functional disor-
ders, from these we excluded subjects with Helicobacter pylori
infection, known to modify the expression of IL-21 [21]. The
analysis of the expression of c-REL gene was performed in
mucosal biopsy samples from 10 CD cases, 10 potential CD
patients (5 M0 and 5 M1), and 10 controls.
Statistical Analysis
Frequencies were compared by the x
2 test with.05 probability of
the null hypothesis. Skewed variables were log transformed when
required. Expression data were compared by a signed Rank test
for independent samples. Data analysis was performed using:
Prism (GraphPad Software, San Diego, CA), SPSS 15 (SPSS Inc.,
Chicago, IL, USA) and Haploview 4.1.
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